PAI
Palo Alto Investors Portfolio holdings
AUM
$470M
1-Year Return
2.57%
This Quarter Return
+3.08%
1 Year Return
+2.57%
3 Year Return
+93.77%
5 Year Return
+190.64%
10 Year Return
+955.02%
AUM
$1.24B
AUM Growth
+$30.7M
(+2.5%)
Cap. Flow
+$28.2M
Cap. Flow
% of AUM
2.28%
Top 10 Holdings %
Top 10 Hldgs %
87.1%
Holding
32
New
2
Increased
4
Reduced
3
Closed
2
Top Buys
| 1 |
NovoCure
NVCR
|
+$22.6M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$10.8M |
| 3 |
NVRO
NEVRO CORP.
NVRO
|
+$4.73M |
| 4 |
STAAR Surgical
STAA
|
+$1.45M |
| 5 |
Relmada Therapeutics
RLMD
|
+$468K |
Top Sells
| 1 |
PRVB
Provention Bio, Inc. Common Stock
PRVB
|
+$9.42M |
| 2 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
+$1.05M |
| 3 |
Vanda Pharmaceuticals
VNDA
|
+$1.05M |
| 4 |
Prothena Corp
PRTA
|
+$431K |
| 5 |
PKBO
Peak Bio, Inc. Common Stock
PKBO
|
+$314K |
Sector Composition
| 1 | Healthcare | 98.22% |
| 2 | Financials | 1.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Kezar Life Sciences
KZR
$29.1M
| $1.61M | 0.13% |
65,620
| – | – |
|
27
Aldeyra Therapeutics
ALDX
$330M
| $1.35M | 0.11% |
160,800
| – | – |
|
|
GRTS
28
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $1.3M | 0.1% |
666,127
| – | – |
|
29
Tactile Systems Technology
TCMD
$306M
| $676K | 0.05% |
27,100
| – | – |
|
30
UroGen Pharma
URGN
$873M
| $254K | 0.02% |
24,500
| – | – |
|
|
PRVB
31
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| – | – |
-390,800
| Closed | -$9.42M |
|
|
PKBO
32
DELISTED
Peak Bio, Inc. Common Stock
PKBO
| – | – |
-497,528
| Closed | -$314K |
|